Ahmed Sameh A, Yar Abdulaziz A, Ghaith Anas M, Alahmadi Rayan N, Almaleki Faisal A, Alahmadi Hassan S, Almaramhy Waleed H, Alsaedi Ahmed M, Alraddadi Man K, Ismail Hussein M
Department of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Madinah 42353, Saudi Arabia.
Department of Internal Medicine, College of Medicine, Taibah University, Madinah 42353, Saudi Arabia.
Diseases. 2025 Jan 11;13(1):12. doi: 10.3390/diseases13010012.
BACKGROUND/OBJECTIVES: Vitamin K2 analogs are associated with decreased vascular calcification, which may provide protective benefits for individuals with coronary artery disease (CAD) by stimulating anti-calcific proteins like matrix Gla protein and adjusting innate immune responses. This study addresses a significant gap in understanding the association between serum levels of vitamin K2 analogs in different CAD types and examines their correlations with clinical risk parameters in CAD patients.
This case-control study enrolled CAD patients and healthy controls to assess and compare serum concentrations of two vitamin K2 analogs including menaquinone-4 (MK-4) and menaquinone-7 (MK-7) via ultra-performance liquid chromatography with tandem mass spectrometry (UPLC-MS/MS). CAD risk factors were evaluated and related to serum levels of vitamin K2 analogs. The CAD group was further subdivided into stable angina, STEMI, NSTEMI, and unstable angina groups to investigate potential differences in vitamin K2 analog levels.
Patients experiencing acute coronary syndrome exhibited notably reduced serum levels of MK-4 and MK-7 (1.61 ± 0.66, and 1.64 ± 0.59 ng/mL, respectively) in comparison to the control group (2.29 ± 0.54, and 2.16 ± 0.46 ng/mL, respectively), with MK-4 and MK-7 displaying stronger associations with CAD risk indicators. Notable variations in vitamin K2 analog levels were found between CAD patients and control groups ( < 0.001). Unstable angina patients showed the lowest serum levels of MK-4 and MK-7.
The present study demonstrated a higher prevalence rate of vitamin K2 deficiency among patients with CAD. The most pronounced decrease in MK-4 and MK-7 was observed in unstable angina patients. Moreover, these outcomes indicate the imperative requirement for an integrative approach that incorporates metabolic, lipid, and vitamin K2-related pathways in the risk stratification and management of CAD.
背景/目的:维生素K2类似物与血管钙化减少有关,通过刺激抗钙化蛋白(如基质Gla蛋白)和调节先天免疫反应,可能为冠心病(CAD)患者提供保护作用。本研究填补了在理解不同CAD类型中维生素K2类似物血清水平之间的关联方面的重大空白,并研究了它们与CAD患者临床风险参数的相关性。
本病例对照研究纳入CAD患者和健康对照,通过超高效液相色谱串联质谱法(UPLC-MS/MS)评估和比较两种维生素K2类似物(包括甲萘醌-4(MK-4)和甲萘醌-7(MK-7))的血清浓度。评估CAD风险因素并将其与维生素K2类似物的血清水平相关联。CAD组进一步细分为稳定型心绞痛、ST段抬高型心肌梗死、非ST段抬高型心肌梗死和不稳定型心绞痛组,以研究维生素K2类似物水平的潜在差异。
与对照组(分别为2.29±0.54和2.16±0.46 ng/mL)相比,急性冠状动脉综合征患者的MK-4和MK-7血清水平显著降低(分别为1.61±0.66和1.64±0.59 ng/mL),MK-4和MK-7与CAD风险指标的关联更强。CAD患者和对照组之间维生素K2类似物水平存在显著差异(<0.001)。不稳定型心绞痛患者的MK-4和MK-7血清水平最低。
本研究表明CAD患者中维生素K2缺乏的患病率较高。在不稳定型心绞痛患者中观察到MK-4和MK-7下降最为明显。此外,这些结果表明在CAD的风险分层和管理中,迫切需要一种整合代谢、脂质和维生素K2相关途径的综合方法。